
ENDxTB

Evaluation of new diagnostics for incident, active, and recurrent TB





Acronym

ENDxTB

Full Title

Evaluation of new diagnostics for incident, active, and recurrent TB

Programme

National Institutes of Health (NIH)

Grant number

1U01AI152075

ABSTRACT

A central component of WHO's End TB Strategy is to diagnose approximately 3 million patients annually who are not diagnosed or treated due to inadequate tests that are not tailored towards specific needs for different levels or capabilities of health care facilities

Better tests are needed at point-of-care, where triage in low-resource settings is essential to prioritise those with the highest risk for tuberculosis disease to higher levels of care. On the other hand, more complex, resource-intensive tests aimed at specific phases of host-pathogen interaction, like at the end of treatment or during latent infection would complement community-based diagnosis in less-developed health care systems that have access to central, specialised laboratory facilities.

Wide-ranging diagnostic capacities co-exist in different regions of the same country, for instance in rural versus urban areas and therefore, a comprehensive battery of diagnostic tests that are appropriate for specific settings are needed. Meeting the End TB Strategy targets will also require dramatically improved prevention of disease approaches to block transmission. With 1.7 billion people latently infected, it is not cost-effective to provide prophylaxis to all. Hence a test that could predict those most at risk of developing disease would enable targeted therapeutic approaches. Similarly, tests to enable personalised or stratified treatment strategies are urgently needed.

The goal of ENDxTB is to conduct a clinical research program across the globe to compare side-by-side the most promising new tests for a wide range of health care settings in experienced clinical sites in Africa (South Africa, The Gambia), and Southeast Asia (Vietnam), and advanced laboratories in the USA and Europe. The cohorts include adults, children, and people living with HIV. The new assays include: 1) at point-of-care: sputum-free assays, including two triage tests, based on detection of host proteins and host transcripts, both on fingerstick blood, and a

high-sensitivity urinary lipoarabinomannan assay; and 2) at central laboratories: a multiplex qRT-PCR test for mRNA signatures for progression to tuberculosis, and a host 4-protein biosignature in blood for prediction of poor treatment outcome.

The performance of these tests will be evaluated according to internationally established target product profiles for the respective health care levels. ENDxTB Project will identify the best tests for different health care levels and for different phases of infection and disease. The multi-disciplinary team of test developers and clinical scientists, and the selection of cohorts are well suited to identify novel technologies towards meeting the End TB milestones.

Duration

68 months (17/06/2020 - 31/01/2026)

Project Funding

7,499,882 USD

Principal Investigators

- Prof Gerhard Walzl, Stellenbosch University
- Prof Jayne Sutherland, MRC Unit The Gambia at LSHTM
- Prof John Belisle, Colorado State University

Partners

- University of Stellenbosch, South Africa
- MRC Unit The Gambia at LSHTM, The Gambia
- Colorado State University, USA
- SATVI, University of Cape Town, South Africa
- Oxford University Clinical Research Unit, Vietnam
- Leiden University Medical Center, The Netherlands
- LINQ management GmbH, Germany

Project Management

LINQ management GmbH Britta Theobald-Loeffler

Phone: +49 (0)152 08301195

Email: b.theobald-loeffler@linq-management.com

Project Website

www.endxtb.com